Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma Nat Rev Dis Primers. 2021;7(1):65.

Article  PubMed  Google Scholar 

Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma Pathologica. 2021;113(3):158–69.

Article  PubMed  Google Scholar 

Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-generation biomarkers for Cholangiocarcinoma. Cancers (Basel). 2021;13(13).

Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs. 2021;30(4):429–38.

Article  CAS  PubMed  Google Scholar 

Liu J, Ren WX, Shu J. Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma. Insights Imaging. 2022;13(1):10.

Article  PubMed  PubMed Central  Google Scholar 

Wang M, Chen Z, Guo P, Wang Y, Chen G. Therapy for advanced cholangiocarcinoma: current knowledge and future potential. J Cell Mol Med. 2021;25(2):618–28.

Article  PubMed  Google Scholar 

Rizzo A, Frega G, Ricci AD, et al. Anti-EGFR monoclonal antibodies in advanced biliary Tract Cancer: a systematic review and Meta-analysis. Vivo. 2020;34(2):479–88.

Article  CAS  Google Scholar 

Rizzo A, Ricci AD, Tober N, et al. Second-line treatment in advanced biliary Tract Cancer: today and tomorrow. Anticancer Res. 2020;40(6):3013–30.

Article  CAS  PubMed  Google Scholar 

Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):547–54.

Article  CAS  PubMed  Google Scholar 

Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021;27:100354.

Article  PubMed  Google Scholar 

Vignone A, Biancaniello F, Casadio M et al. Emerging therapies for Advanced Cholangiocarcinoma: an updated literature review. J Clin Med. 2021;10(21).

Mollica V, Rizzo A, Marchetti A, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023;23(8):5039–49.

Article  CAS  PubMed  Google Scholar 

Skouteris N, Papageorgiou G, Fioretzaki R, et al. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma. Immunotherapy. 2023;15(7):487–502.

Article  CAS  PubMed  Google Scholar 

Zeng FL, Chen JF. Application of Immune checkpoint inhibitors in the treatment of Cholangiocarcinoma. Technol Cancer Res Treat. 2021;20:15330338211039952.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santoni M, Rizzo A, Mollica V, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596.

Article  PubMed  Google Scholar 

Chen R, Zheng D, Li Q, et al. Immunotherapy of cholangiocarcinoma: therapeutic strategies and predictive biomarkers. Cancer Lett. 2022;546:215853.

Article  CAS  PubMed  Google Scholar 

Yu X, Zhu L, Wang T, Chen J. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. Front Immunol. 2023;14:1037945.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katoh M, Katoh M. WNT signaling and cancer stemness. Essays Biochem. 2022;66(4):319–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer Stemness meets immunity: from mechanism to Therapy. Cell Rep. 2021;34(1):108597.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomei S, Ibnaof O, Ravindran S, Ferrone S, Maccalli C. Cancer Stem cells are possible key players in regulating Anti-tumor Immune responses: the role of Immunomodulating molecules and MicroRNAs. Cancers (Basel). 2021;13(7).

Shi X, Liu Y, Cheng S, et al. Cancer Stemness Associated with prognosis and the efficacy of Immunotherapy in Adrenocortical Carcinoma. Front Oncol. 2021;11:651622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang YJ, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. Am J Physiol Cell Physiol. 2015;309(11):C709–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016;51:1–9.

Article  CAS  PubMed  Google Scholar 

Choodetwattana P, Proungvitaya S, Jearanaikoon P, Limpaiboon T. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell lines. Asian Pac J Cancer Prev. 2019;20(9):2745–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med. 2014;2(11):109.

PubMed  PubMed Central  Google Scholar 

Papaccio F. Circulating cancer stem cells: an interesting niche to explore. Explor Target Antitumor Ther. 2020;1(4):253–58.

Article  PubMed  PubMed Central  Google Scholar 

Kantara C, O’Connell MR, Luthra G, et al. Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab Invest. 2015;95(1):100–12.

Article  CAS  PubMed  Google Scholar 

Li M, Zhang B, Zhang Z, et al. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. Biomed Res Int. 2014;2014:981261.

PubMed  PubMed Central  Google Scholar 

Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg. 2011;254(4):569–76.

Article  PubMed  Google Scholar 

Committee CSCOGW. Guidelines of Chinese Society of Clinical Oncology, biliary Tract Cancer (2020). Beijing: People’s Medical Publishing House; 2020.

Google Scholar 

Wu S, Liu S, Liu Z, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS ONE. 2015;10(4):e0123976.

Article  PubMed  PubMed Central  Google Scholar 

Li S, Chen Q, Li H, Wu Y, Feng J, Yan Y. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer. Clin Transl Oncol. 2017;19(9):1147–53.

Article  CAS  PubMed  Google Scholar 

Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–80.

Article  PubMed  Google Scholar 

Halder R, Amaraneni A, Shroff RT. Cholangiocarcinoma: a review of the literature and future directions in therapy. Hepatobiliary Surg Nutr. 2022;11(4):555–66.

Article  PubMed  PubMed Central  Google Scholar 

Liu T, Sun B, Zhao X, et al. OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci. 2014;15(11):19634–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Liu T, Zhang S, Guo K, Liu Y. Oct4 induces EMT through LEF1/beta-catenin dependent WNT signaling pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(4):2599–606.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szczerba A, Sliwa A, Pieta PP, Jankowska A. The role of circulating Tumor cells in Ovarian Cancer Dissemination. Cancers (Basel). 2022;14(24).

Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miranda A, Hamilton PT, Zhang AW, et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc Natl Acad Sci U S A. 2019;116(18):9020–29.

Article